FR2768623A1 - Compositions comprising anti-seborrheic, anti-hyperkeratinization and anti-inflammatory agents - Google Patents

Compositions comprising anti-seborrheic, anti-hyperkeratinization and anti-inflammatory agents Download PDF

Info

Publication number
FR2768623A1
FR2768623A1 FR9711967A FR9711967A FR2768623A1 FR 2768623 A1 FR2768623 A1 FR 2768623A1 FR 9711967 A FR9711967 A FR 9711967A FR 9711967 A FR9711967 A FR 9711967A FR 2768623 A1 FR2768623 A1 FR 2768623A1
Authority
FR
France
Prior art keywords
composition according
vitamin
complex
hyperkeratinization
palmitate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR9711967A
Other languages
French (fr)
Other versions
FR2768623B1 (en
Inventor
Jean Noel Thorel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to FR9711967A priority Critical patent/FR2768623B1/en
Publication of FR2768623A1 publication Critical patent/FR2768623A1/en
Application granted granted Critical
Publication of FR2768623B1 publication Critical patent/FR2768623B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/008—Preparations for oily skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/27—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/676—Ascorbic acid, i.e. vitamin C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/678—Tocopherol, i.e. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/75—Anti-irritant

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compositions for the treatment of oily skin comprise a combination of anti-seborrheic, anti-hyperkeratinization and anti-inflammatory agents. Compositions for the treatment of oily skin comprises a complex of one or more anti-seborrheic agents, a complex of one or more anti-hyperkeratinization agents and an anti-inflammatory complex consisting of one or more agents with restructuring and/or soothing activity.

Description

La présente invention concerne une composition cosmétique et/ou dermatologique destinée à une application topique pour le traitement des peaux grasses et des dermatoses qui leur sont associées, notamment l'acné.The present invention relates to a cosmetic and / or dermatological composition intended for topical application for the treatment of oily skin and the dermatoses associated therewith, in particular acne.

Une peau grasse présente une hypersécrétion sébacée. Cette dernière est due à une hypersensibilité des glandes sébacées aux androgènes et/ou à une hyperactivité de la 5-alpha réductase, enzyme responsable de la conversion de la testostérone en dihydrotestostérone, puissant stimulant de la sécrétion sébacée.Oily skin has sebaceous hypersecretion. The latter is due to hypersensitivity of the sebaceous glands to androgens and / or to hyperactivity of 5-alpha reductase, the enzyme responsible for the conversion of testosterone to dihydrotestosterone, a powerful stimulant of sebaceous secretion.

L'épiderme des peaux grasses est souvent épais du fait d'une mauvaise desquamation naturelle. De plus, il présente une hyperkératinisation au niveau du canal folliculaire, qui entraîne l'obstruction du follicule par un bouchon corné et donc la formation de microkistes et comédons. Ces derniers dégénèrent ensuite en boutons. Cette hyperkératose de l'épiderme est liée à l'action irritante des acides gras contenus dans le sébum, libérés lors de la dégradation des triglycérides par les bactéries et les levures présentes à la surface de la peau (propionibacterium acnes et pityrosporum ovale).The epidermis of oily skin is often thick due to poor natural scaling. In addition, it has hyperkeratinization in the follicular canal, which leads to the obstruction of the follicle by a horny plug and therefore the formation of microkists and blackheads. These then degenerate into buttons. This hyperkeratosis of the epidermis is linked to the irritating action of the fatty acids contained in the sebum, released during the breakdown of triglycerides by bacteria and yeasts present on the surface of the skin (propionibacterium acnes and pityrosporum ovale).

La prolifération bactérienne, source d'acides gras libres irritants, associée à la rupture des microkystes et des comédons dans le derme, entraîne une inflammation.Bacterial overgrowth, a source of irritating free fatty acids, associated with the rupture of microcysts and comedones in the dermis, leads to inflammation.

L'hyperséborrhée entraîne l'hyperkératinisation- et l'inflammation, qui ellesinêmes activent la sécrétion séborrhéique. Ces troubles cutanés caractéristiques des peaux grasses sont donc directement lés et intriqués.Hyperseborrhea leads to hyperkeratinization and inflammation, which themselves activate seborrheic secretion. These skin disorders characteristic of oily skin are therefore directly damaged and entangled.

On trouve sur le marché de nombreuses compositions cosmétiques et/ou dermatologiques destinées à traiter les dermatoses séborrhéiques. Pour se faire, elles contiennent des actifs qui régulent le flux sébacé et suppriment donc la cause initiale des troubles cutanés des peaux grasses. II subsiste donc le besoin d'actifs topiques ayant un effet à la fois sur l'hypersécrétion sébacée, sur l'hyperkératinisation et sur l'inflammation afin d'obtenir un traitement efficace des peaux grasses.There are many cosmetic and / or dermatological compositions on the market intended for treating seborrheic dermatoses. To do this, they contain active ingredients that regulate the sebaceous flow and therefore eliminate the initial cause of skin disorders of oily skin. There therefore remains the need for topical active agents which have an effect both on sebaceous hypersecretion, on hyperkeratinization and on inflammation in order to obtain an effective treatment for oily skin.

A la suite d'importantes recherches menées dans le domaine du traitement des peaux grasses, la demanderesse a mis au point une composition qui permet de traiter l'hyperséborrhée, l'hyperkératinisation et l'inflammation caractéristiques des dermatoses séborrhéiques.Following significant research carried out in the field of treatment of oily skin, the applicant has developed a composition which makes it possible to treat the hyperseborrhea, hyperkeratinization and inflammation characteristic of seborrheic dermatoses.

L'objet de la présente invention est donc une composition cosmétique et/ou dermatologique pour le traitement des peaux grasses, caractérisée par le fait qu'elle comprend en combinaison, un complexe composé par un ou plusieurs actifs présentant des propriétés antiséborrhéiques, un complexe constitué par un ou plusieurs actifs traitant l'hyperkératinisation et un complexe antiinflammatoire constitué par un ou plusieurs actifs restructurants et/ou apaisants.The object of the present invention is therefore a cosmetic and / or dermatological composition for the treatment of oily skin, characterized in that it comprises in combination, a complex composed of one or more active agents having antiseborrheic properties, a complex consisting by one or more active agents treating hyperkeratinization and an anti-inflammatory complex constituted by one or more restructuring and / or soothing active agents.

Le complexe anti-séborrhéique selon l'invention est composé de sels de zinc, de vitamine B5 (d-panthénol) et de vitamine B6 (pyridoxine).The anti-seborrheic complex according to the invention is composed of zinc salts, vitamin B5 (d-panthenol) and vitamin B6 (pyridoxine).

Les sels de zinc utilisés dans la composition selon l'invention sont avantageusement apportés sous forme de gluconate de zinc. Ce dernier de par sont pouvoir d'inhibition de la 5-alpha réductase, intervient dans la régulation du flux sébacé. Les vitamines B5 et B6 utilisées en association avec le gluconate de zinc, complètent son activité sébo-modulatrice et la potentialise.The zinc salts used in the composition according to the invention are advantageously provided in the form of zinc gluconate. The latter by virtue of their 5-alpha reductase inhibition power, is involved in the regulation of sebaceous flux. Vitamins B5 and B6 used in combination with zinc gluconate, complement its sebum-modulating activity and potentiate it.

Le complexe traitant l'hyperkératinisation selon l'invention comprend un ester rétinique et un alpha hydroxyacide. Selon une composition particulièrement préférée de l'invention, L'ester rétinique est le palmitate de Vitamine A, L'alpha hydroxy acide est l'acide citrique.The complex treating hyperkeratinization according to the invention comprises a retinal ester and an alpha hydroxy acid. According to a particularly preferred composition of the invention, the retinal ester is the palmitate of Vitamin A, the alpha hydroxy acid is citric acid.

L'acide citrique a un effet kératolytique, il débarrasse l'épiderme de ses impuretés et de l'excès de sébum. Le palmitate de Vitamine A a un effet kératomodulateur, il agit plus en profondeur et stimule la multiplication des cellules de l'épiderme.Citric acid has a keratolytic effect, it rids the epidermis of its impurities and excess sebum. Vitamin A palmitate has a keratomodulatory effect, it acts more deeply and stimulates the multiplication of epidermal cells.

Acide citrique et vitamine A conduisent donc à une diminution de l'épaisseur de la couche cornée et à l'assouplissement de l'épiderme.Citric acid and vitamin A therefore lead to a reduction in the thickness of the stratum corneum and softening of the epidermis.

Le complexe anti-inflammatoire selon l'invention est composé par l'association de un ou plusieurs agents antiradicalaires et de un ou plusieurs monosaccharides.The anti-inflammatory complex according to the invention is composed by the combination of one or more anti-free radical agents and one or more monosaccharides.

Les agents antiradicalaires peuvent être la superoxyde dismutase (SOD), des dérivés de Vitamine C ou des dérivés de Vitamine E. Les monosaccharides sont choisis de préférence parmi le fucose et le rhamnose. Selon une composition particulièrement préférée de l'invention, on utilise la SOD en association avec du palmitate d'ascorbyle comme dérivé de la Vitamine C et avec de l'acétate de tocophérol comme dérivé de Vitamine E. A ces actifs anti-radicalaires restructurants, on associe un mélange de fucose et de rhamnose qui a un effet apaisant.The anti-free radical agents may be superoxide dismutase (SOD), derivatives of Vitamin C or derivatives of Vitamin E. The monosaccharides are preferably chosen from fucose and rhamnose. According to a particularly preferred composition of the invention, SOD is used in combination with ascorbyl palmitate as derivative of Vitamin C and with tocopherol acetate as derivative of Vitamin E. With these restructuring anti-radical active agents, we combine a mixture of fucose and rhamnose which has a soothing effect.

Le complexe antilnflammatoire selon l'invention peut également contenir un agent antiseptique. Selon une composition particulièrement préférée de l'invention, on utilise le sorbate de potassium, antiseptique particulièrement bien toléré.The anti-inflammatory complex according to the invention can also contain an antiseptic agent. According to a particularly preferred composition of the invention, potassium sorbate is used, an antiseptic which is particularly well tolerated.

Les proportions les plus appropriées de chacun des constituants de la composition selon l'invention sont les suivantes, ces proportions étant exprimées en pourcentage en poids par rapport au poids total de la composition: - gluconate de zinc : 0,1 à 1% - vitamine B5 (d-panthénol) : 0,1 à 1% - vitamine B6 (pyridoxine) : 0,01 à 0,1 % - acide citrique : 0,1 à 0,5% - palmitate de vitamine A : 0,01 à 1% - SOD: 0,01 à 1% - palmitate d'ascorbyle : 0,01 à 1% - acétate de tocophérol : 0,1 à 5% - fucose: 0,01 à 4% - rhamnose : 0,1 à 5% - sorbate de potassium : 0,1 à 0,6 %
La composition selon l'invention peut se présenter sous toutes les formes galéniques classiquement utilisées dans les compositions cosmétiques ou dermatologiques.The most appropriate proportions of each of the constituents of the composition according to the invention are as follows, these proportions being expressed as a percentage by weight relative to the total weight of the composition: - zinc gluconate: 0.1 to 1% - vitamin B5 (d-panthenol): 0.1 to 1% - vitamin B6 (pyridoxine): 0.01 to 0.1% - citric acid: 0.1 to 0.5% - vitamin A palmitate: 0.01 to 1% - SOD: 0.01 to 1% - ascorbyl palmitate: 0.01 to 1% - tocopherol acetate: 0.1 to 5% - fucose: 0.01 to 4% - rhamnose: 0.1 to 5% - potassium sorbate: 0.1 to 0.6%
The composition according to the invention can be in all the galenical forms conventionally used in cosmetic or dermatological compositions.

Les compositions selon l'invention peuvent en outre contenir tous les constituants classiquement utilisés dans les compositions cosmétiques et/ou dermatologiques.The compositions according to the invention may also contain all the constituents conventionally used in cosmetic and / or dermatological compositions.

Les compositions selon l'invention peuvent de plus contenir des actifs autres que ceux précédemment cités, et classiquement utilisés dans les compositions cosmétiques et/ou dermatologiques.The compositions according to the invention may also contain active agents other than those previously mentioned, and conventionally used in cosmetic and / or dermatological compositions.

Des exemples concrets mais nullement limitatifs, illustrant l'invention, vont maintenant être donnés.Concrete but in no way limiting examples illustrating the invention will now be given.

Exemple 1:
Triglycéride caprylique/caprique/succinique 1 à 10 %
Palmitate d'ascorbyle 0,01 à 0,1 %
Stéarate de glycéryle 1 à 5%
Acide stéarique 1 à 5%
Acétate de tocophérol 0,1 à 1 %
Triglycéride caprylique/caprique 1 à 15 OJo
Pyridoxine 0,01 à 0,05 %
Acide citrique 0,1 à 0,5 %
Gluconate de zinc 0,1 à 1 %
Citrate trisodique 1 à 2,5 %
L-Arginine 0,1 à 2 %
Glycérine 1 à 4%
Palmitate de vitamine A 0,01 à 1 % d-Panthénol 0,1 à 1 %
Rhamnose 0,1 à 1 %
L+ucose 0,01 à 1 %
Lactoferrine / Lactoperoxydase 0,01 à 1 %
Superoxyde dismutase 0,01 à 1 %
Polyacrylamide / C13-14 isoparaffine / Laureth-7 0,2 à 1 %
Eau qsp. 100 %
Exemple 2:
Polymère d'acide acrylique 0,1 - 1,5 %
Acide glycyrrhétinique 0,1 - 1 %
Triéthanolamine 0,1 - 2 %
Butylène glycol 0,5 - 4 %
Palmitate d'ascorbyle 0,01 à 0,1 %
Acétate de tocophérol 0,1 à 1 %
Pyridoxine 0,01 à 0,05 %
Acide citrique 0,1 à 0,5 %
Gluconate de zinc 0,1 à 1 %
Citrate trisodique 1 à 2,5 %
L-Arginine 0,1 à 2 %
Palmitate de vitamine A 0,01 à 1 % d-Panthénol 0,1 à 1 %
L+ucose 0,01 à 1 %
Lactoferrine / Lactoperoxydase 0,01 à 1 %
Superoxyde dismutase 0,01 à 1 %
Sorbate de potassium 0,1 à 0,6 %
Conservateurs qs.Example 1:
Caprylic / capric / succinic triglyceride 1 to 10%
Ascorbyl palmitate 0.01 to 0.1%
Glyceryl stearate 1 to 5%
1 to 5% stearic acid
Tocopherol acetate 0.1 to 1%
Caprylic / capric triglyceride 1 to 15 OJo
Pyridoxine 0.01 to 0.05%
Citric acid 0.1 to 0.5%
Zinc gluconate 0.1 to 1%
Trisodium citrate 1 to 2.5%
L-Arginine 0.1 to 2%
Glycerin 1 to 4%
Vitamin A palmitate 0.01 to 1% d-Panthenol 0.1 to 1%
Rhamnose 0.1 to 1%
L + ucose 0.01 to 1%
Lactoferrin / Lactoperoxidase 0.01 to 1%
Superoxide dismutase 0.01 to 1%
Polyacrylamide / C13-14 isoparaffin / Laureth-7 0.2 to 1%
Water qs. 100%
Example 2:
Polymer of acrylic acid 0.1 - 1.5%
Glycyrrhetinic acid 0.1 - 1%
Triethanolamine 0.1 - 2%
Butylene glycol 0.5 - 4%
Ascorbyl palmitate 0.01 to 0.1%
Tocopherol acetate 0.1 to 1%
Pyridoxine 0.01 to 0.05%
Citric acid 0.1 to 0.5%
Zinc gluconate 0.1 to 1%
Trisodium citrate 1 to 2.5%
L-Arginine 0.1 to 2%
Vitamin A palmitate 0.01 to 1% d-Panthenol 0.1 to 1%
L + ucose 0.01 to 1%
Lactoferrin / Lactoperoxidase 0.01 to 1%
Superoxide dismutase 0.01 to 1%
Potassium sorbate 0.1 to 0.6%
Preservatives qs.

Eau qsp.l 00 %
Exemple 3
Propylène glycol 1 - 8 %
Monolaurate de sorbitan 0,5 - 5 %
Diméthicone copolyol 0,1 - 5 %
Acide salicylique 0,1 - 0,5 %
Disodium EDTA 0,05 - 0,5 %
Gluconate de zinc 0,1 - 1 %
Palmitate d'ascorbyle 0,01 à 0,1 %
Acétate de tocophérol 0,1 à 1 %
Pyridoxine 0,01 à 0,05 %
Acide citrique 0,1 - 0,5 %
Chlorure de sodium 0,1 - 1,5 %
Citrate trisodique 1 à 2,5 %
L-Arginine 0,1 à 2 %
Palmitate de vitamine A 0,01 à 1 % dCanthénol 0,1 à 1 %
Rhamnose 0,1 à 1 %
L+ucose 0,01 à 1 %
Lactoferrine / Lactoperoxydase 0,01 à 1 %
Superoxyde dismutase 0,01 à 1 %
Conservateurs qs.Water qs.l 00%
Example 3
Propylene glycol 1 - 8%
Sorbitan monolaurate 0.5 - 5%
Dimethicone copolyol 0.1 - 5%
Salicylic acid 0.1 - 0.5%
Disodium EDTA 0.05 - 0.5%
Zinc gluconate 0.1 - 1%
Ascorbyl palmitate 0.01 to 0.1%
Tocopherol acetate 0.1 to 1%
Pyridoxine 0.01 to 0.05%
Citric acid 0.1 - 0.5%
Sodium chloride 0.1 - 1.5%
Trisodium citrate 1 to 2.5%
L-Arginine 0.1 to 2%
Vitamin A palmitate 0.01 to 1% dCanthenol 0.1 to 1%
Rhamnose 0.1 to 1%
L + ucose 0.01 to 1%
Lactoferrin / Lactoperoxidase 0.01 to 1%
Superoxide dismutase 0.01 to 1%
Preservatives qs.

Eau qsp.l 00 % Water qs.l 00%

Claims (10)

1- Composition cosmétique et/ou dermatologique pour le traitement des peaux grasses, caractérisée par le fait qu'elle comprend en combinaison, un complexe composé par un ou plusieurs actifs présentant des propriétés anti-séborrhéiques, un complexe constitué par un ou plusieurs actifs traitant l'hyperkératinisation et un complexe anti-inflammatoire constitué par un ou plusieurs actifs restructurants et/ou apaisants. 1- Cosmetic and / or dermatological composition for the treatment of oily skin, characterized in that it comprises, in combination, a complex composed of one or more active agents having anti-seborrheic properties, a complex consisting of one or more active agents treating hyperkeratinization and an anti-inflammatory complex consisting of one or more restructuring and / or soothing active ingredients. REVENDICATIONS 2- Composition selon la revendication 1, caractérisée par le fait que le complexe anti-séborrhéique est composé de sels de zinc, de vitamine B5 et de vitamine 2- Composition according to claim 1, characterized in that the anti-seborrheic complex is composed of zinc salts, vitamin B5 and vitamin B6.B6. 3- Composition selon la revendication 2, caractérisée par le fait que les sels de zinc sont apportés sous forme de gluconate de zinc. 3- Composition according to claim 2, characterized in that the zinc salts are provided in the form of zinc gluconate. 4- Composition selon l'une quelconque des revendications 1 à 3, caractérisée par le fait que le complexe traitant l'hyperkératinisation comprend un ester rétinique et un alpha hydroxyacide. 4- Composition according to any one of claims 1 to 3, characterized in that the complex treating hyperkeratinization comprises a retinal ester and an alpha hydroxy acid. 5- Composition selon la revendication 4, caractérisé par le fait que l'ester rétinique est le palmitate de vitamine A. 5- Composition according to claim 4, characterized in that the retinal ester is palmitate of vitamin A. 6- Composition selon la revendication 4 ou 5, caractérisée par le fait que l'alpha hydroxyacide est l'acide citrique. 6- Composition according to claim 4 or 5, characterized in that the alpha hydroxy acid is citric acid. 7- Composition selon l'une quelconque des revendications 1 à 6, caractérisée par le fait que le complexe anti-inflammatoire est composé de un ou plusieurs antiradicalaires et de un ou plusieurs monosaccharides. 7- Composition according to any one of claims 1 to 6, characterized in that the anti-inflammatory complex is composed of one or more anti-free radicals and one or more monosaccharides. 8- Composition selon la revendication 7, caractérisée par le fait que le complexe anti-inflammatoire est constitué par la SOD, le palmitate d'ascorbyle, l'acétate de tocophérol, le flicose et le rhamnose. 8- Composition according to claim 7, characterized in that the anti-inflammatory complex consists of SOD, ascorbyl palmitate, tocopherol acetate, flicose and rhamnose. 9- Composition selon l'une des revendications 1 à 8, caractérisée par le fait que le complexe anti-inflammatoire contient un agent antiseptique, et préférentiellement du sorbate de potassium.  9- Composition according to one of claims 1 to 8, characterized in that the anti-inflammatory complex contains an antiseptic agent, and preferably potassium sorbate. 10- Composition selon l'une quelconque des revendications 1 à 9, caractérisée par le fait qu'elle comprend les composés dans les proportions suivantes, ces proportions étant exprimées en pourcentage en poids par rapport au poids total de la composition  10- Composition according to any one of claims 1 to 9, characterized in that it comprises the compounds in the following proportions, these proportions being expressed as a percentage by weight relative to the total weight of the composition - gluconate de zinc : 0,1 à 1% - zinc gluconate: 0.1 to 1% - vitamine B5 (d-panthénol) : 0,1 à 1% - vitamine B6 (pyridoxine) 0,01 à 0,1%  - vitamin B5 (d-panthenol): 0.1 to 1% - vitamin B6 (pyridoxine) 0.01 to 0.1% - acide citrique; 0, 1 à 0,5% - citric acid; 0.1 to 0.5% - palmitate de vitamine A : 0,01 à 1% - vitamin A palmitate: 0.01 to 1% - SOD: 0,01 à 1% - SOD: 0.01 to 1% - palmitate d'ascorbyle : 0,01 à 1% - ascorbyle palmitate: 0.01 to 1% - acétate de tocophérol : 0,1 à 5% - tocopherol acetate: 0.1 to 5% - fucose : 0,01 à 4%  - fucose: 0.01 to 4% - rhamnose: 0,1 à 5% - rhamnose: 0.1 to 5% - sorbate de potassium: 0,1 à 0,6 %  - potassium sorbate: 0.1 to 0.6%
FR9711967A 1997-09-22 1997-09-22 COSMETIC AND / OR DERMATOLOGICAL COMPOSITION FOR TOPICAL USE FOR THE TREATMENT OF OILY SKIN Expired - Lifetime FR2768623B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR9711967A FR2768623B1 (en) 1997-09-22 1997-09-22 COSMETIC AND / OR DERMATOLOGICAL COMPOSITION FOR TOPICAL USE FOR THE TREATMENT OF OILY SKIN

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9711967A FR2768623B1 (en) 1997-09-22 1997-09-22 COSMETIC AND / OR DERMATOLOGICAL COMPOSITION FOR TOPICAL USE FOR THE TREATMENT OF OILY SKIN

Publications (2)

Publication Number Publication Date
FR2768623A1 true FR2768623A1 (en) 1999-03-26
FR2768623B1 FR2768623B1 (en) 1999-12-31

Family

ID=9511493

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9711967A Expired - Lifetime FR2768623B1 (en) 1997-09-22 1997-09-22 COSMETIC AND / OR DERMATOLOGICAL COMPOSITION FOR TOPICAL USE FOR THE TREATMENT OF OILY SKIN

Country Status (1)

Country Link
FR (1) FR2768623B1 (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1055720A2 (en) * 1999-05-28 2000-11-29 JOHNSON & JOHNSON CONSUMER COMPANIES, INC. Compositions for stabilizing oxygen-labile species
WO2001078660A2 (en) * 2000-04-14 2001-10-25 Niadyne Corporation Topical micronutrient delivery system and uses thereof
EP1172080A1 (en) * 2000-07-11 2002-01-16 L'oreal Vitamins and mineral salts composition to reduce the hairloss and/or to promote the hairregrowth
DE10033717A1 (en) * 2000-07-12 2002-01-24 Beiersdorf Ag Cosmetic and dermatological preparation for removing sebum
WO2002019980A1 (en) * 2000-09-11 2002-03-14 Indústria e Comércio de Cosméticos Natura Ltda. Composition of vitamin c and/or vitamin a
FR2813789A1 (en) * 2000-09-11 2002-03-15 Ind E Com De Cosmeticos Natura Composition used for cosmetic treatment of skin comprises vitamin C and/or vitamin A and fucose component
EP1449515A1 (en) * 2003-02-21 2004-08-25 Cognis Deutschland GmbH & Co. KG Anti-acne agents
FR2853539A1 (en) * 2003-04-08 2004-10-15 Ind E Com De Cosmeticos Natura Cosmetic composition with anti-aging effect on the skin contains rhamnose and fucose compounds and excipients, protects hyaluronic acid against decomposition induced by free radicals
WO2005041983A1 (en) 2003-10-31 2005-05-12 Pierre Fabre Dermo-Cosmetique Medicament comprising a reducing alkyl-sugar monomer for the treatment of inflammatory disorders
ITTO20080579A1 (en) * 2008-07-28 2010-01-29 Chiara Cesano COMPOSITION FOR THE REGENERATION OF HYPERTROPHIC TISSUE, RELATED PRODUCTS AND USES
US20100166897A1 (en) * 2008-12-30 2010-07-01 L'oreal Combination of monosaccharides with antioxidants and use thereof
FR2940609A1 (en) * 2008-12-30 2010-07-02 Oreal ASSOCIATION OF MONOSACCHARIDES AND DESQUAMANT AGENTS AND USE THEREOF IN COSMETICS
FR2940612A1 (en) * 2008-12-30 2010-07-02 Oreal ASSOCIATION OF MONOSACCHARIDES WITH ASCORBIC ACID AND ITS USE IN COSMETICS
FR2940610A1 (en) * 2008-12-30 2010-07-02 Oreal ASSOCIATION OF MONOSACCHARIDES WITH C-GLYCOSIDE DERIVATIVES AND ITS USE IN COSMETICS
FR2940608A1 (en) * 2008-12-30 2010-07-02 Oreal USE OF MONOSACCHARIDES AND COMPOSITION
US9421157B2 (en) 2006-07-03 2016-08-23 L'oreal Use of C-glycoside derivatives as pro-desquamating active agents

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704280A (en) * 1986-12-19 1987-11-03 Bates Harry L Cosmetic lotion
EP0250300A1 (en) * 1986-06-16 1987-12-23 Societe Bfb Use of mixtures of zinc salt and vitamin B6 to limit the aloperia and/or the seborrheic processes
DE4242876A1 (en) * 1992-12-18 1994-06-23 Beiersdorf Ag Synergistic combinations of active ingredients for cosmetic and / or dermatological care of the skin and / or the appendages of the skin
DE19509354A1 (en) * 1994-12-08 1996-06-13 Klett Loch Lore M Combination preparation for promoting hair growth and possibly skin and nail growth and for preventing or eliminating hair loss

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0250300A1 (en) * 1986-06-16 1987-12-23 Societe Bfb Use of mixtures of zinc salt and vitamin B6 to limit the aloperia and/or the seborrheic processes
US4704280A (en) * 1986-12-19 1987-11-03 Bates Harry L Cosmetic lotion
DE4242876A1 (en) * 1992-12-18 1994-06-23 Beiersdorf Ag Synergistic combinations of active ingredients for cosmetic and / or dermatological care of the skin and / or the appendages of the skin
DE19509354A1 (en) * 1994-12-08 1996-06-13 Klett Loch Lore M Combination preparation for promoting hair growth and possibly skin and nail growth and for preventing or eliminating hair loss

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1055720A3 (en) * 1999-05-28 2001-03-07 JOHNSON & JOHNSON CONSUMER COMPANIES, INC. Compositions for stabilizing oxygen-labile species
EP1055720A2 (en) * 1999-05-28 2000-11-29 JOHNSON & JOHNSON CONSUMER COMPANIES, INC. Compositions for stabilizing oxygen-labile species
WO2001078660A3 (en) * 2000-04-14 2002-05-23 Niadyne Corp Topical micronutrient delivery system and uses thereof
WO2001078660A2 (en) * 2000-04-14 2001-10-25 Niadyne Corporation Topical micronutrient delivery system and uses thereof
FR2811550A1 (en) * 2000-07-11 2002-01-18 Oreal COMPOSITION BASED ON VITAMINS AND MINERAL SALTS TO REDUCE HAIR LOSS AND / OR PROMOTE HAIR GROWTH
EP1172080A1 (en) * 2000-07-11 2002-01-16 L'oreal Vitamins and mineral salts composition to reduce the hairloss and/or to promote the hairregrowth
DE10033717A1 (en) * 2000-07-12 2002-01-24 Beiersdorf Ag Cosmetic and dermatological preparation for removing sebum
WO2002019980A1 (en) * 2000-09-11 2002-03-14 Indústria e Comércio de Cosméticos Natura Ltda. Composition of vitamin c and/or vitamin a
FR2813789A1 (en) * 2000-09-11 2002-03-15 Ind E Com De Cosmeticos Natura Composition used for cosmetic treatment of skin comprises vitamin C and/or vitamin A and fucose component
EP1449515A1 (en) * 2003-02-21 2004-08-25 Cognis Deutschland GmbH & Co. KG Anti-acne agents
FR2853539A1 (en) * 2003-04-08 2004-10-15 Ind E Com De Cosmeticos Natura Cosmetic composition with anti-aging effect on the skin contains rhamnose and fucose compounds and excipients, protects hyaluronic acid against decomposition induced by free radicals
EP2266580A1 (en) * 2003-10-31 2010-12-29 Pierre Fabre Dermo-Cosmétique Medicament comprising a reducing alkyl-sugar monomer for the treatment of inflammatory disorders
WO2005041983A1 (en) 2003-10-31 2005-05-12 Pierre Fabre Dermo-Cosmetique Medicament comprising a reducing alkyl-sugar monomer for the treatment of inflammatory disorders
US7666847B2 (en) 2003-10-31 2010-02-23 Pierre Fabre Dermo-Cosmetique Medicament comprising a reducing alkyl-sugar monomer for the treatment of inflammatory disorders
US9163049B2 (en) 2003-10-31 2015-10-20 Pierre Fabre Dermo-Cosmetique Medicament comprising a reducing alkyl-sugar monomer for the treatment of inflammatory disorders
US9421157B2 (en) 2006-07-03 2016-08-23 L'oreal Use of C-glycoside derivatives as pro-desquamating active agents
ITTO20080579A1 (en) * 2008-07-28 2010-01-29 Chiara Cesano COMPOSITION FOR THE REGENERATION OF HYPERTROPHIC TISSUE, RELATED PRODUCTS AND USES
FR2940612A1 (en) * 2008-12-30 2010-07-02 Oreal ASSOCIATION OF MONOSACCHARIDES WITH ASCORBIC ACID AND ITS USE IN COSMETICS
FR2940615A1 (en) * 2008-12-30 2010-07-02 Oreal ASSOCIATION OF MONOSACCHARIDES WITH ANTIOXIDANT AGENTS AND ITS USE IN COSMETICS
FR2940608A1 (en) * 2008-12-30 2010-07-02 Oreal USE OF MONOSACCHARIDES AND COMPOSITION
EP2204163A1 (en) * 2008-12-30 2010-07-07 L'oreal Combination of monosaccharides and ascorbic acid and its use in cosmetic
EP2204162A1 (en) * 2008-12-30 2010-07-07 L'oreal Use of monosaccharides and composition
EP2204164A1 (en) * 2008-12-30 2010-07-07 L'oreal Combination of monosaccharides with antioxidizing agents and cosmetic use thereof
US20100173853A1 (en) * 2008-12-30 2010-07-08 L'oreal Combination of monosaccharides with ascorbic acid and use thereof
EP2206491A1 (en) * 2008-12-30 2010-07-14 L'oreal Association of monosaccharides and C-glycoside derivatives and its use in cosmetics
JP2010155837A (en) * 2008-12-30 2010-07-15 L'oreal Sa Combination of monosaccharide and ascorbic acid, and use thereof in cosmetic
FR2940610A1 (en) * 2008-12-30 2010-07-02 Oreal ASSOCIATION OF MONOSACCHARIDES WITH C-GLYCOSIDE DERIVATIVES AND ITS USE IN COSMETICS
EP2223680A3 (en) * 2008-12-30 2013-04-10 L'Oréal Combination of monosaccharides and exfoliating agents and its cosmetic use
US8445459B2 (en) 2008-12-30 2013-05-21 L'oreal Combination of monosaccharide with C-glycoside derivative and use thereof
US9132075B2 (en) 2008-12-30 2015-09-15 L'oreal Combination of monosaccharides with ascorbic acid and use thereof
FR2940609A1 (en) * 2008-12-30 2010-07-02 Oreal ASSOCIATION OF MONOSACCHARIDES AND DESQUAMANT AGENTS AND USE THEREOF IN COSMETICS
US9364411B2 (en) 2008-12-30 2016-06-14 L'oreal Use of monosaccharides and composition therefor
US20100166897A1 (en) * 2008-12-30 2010-07-01 L'oreal Combination of monosaccharides with antioxidants and use thereof
US9974984B2 (en) 2008-12-30 2018-05-22 L'oreal Combination of monosaccharides with antioxidants and use thereof

Also Published As

Publication number Publication date
FR2768623B1 (en) 1999-12-31

Similar Documents

Publication Publication Date Title
FR2768623A1 (en) Compositions comprising anti-seborrheic, anti-hyperkeratinization and anti-inflammatory agents
EP1061895B1 (en) Synergetic composition comprising a compound with lipoaminoacid structure and a tuberous water-lily extract
US5728733A (en) N-acyl-ethylene triacetic composition for treating abnormal keratinization
BE898268A (en) New anti-acne composition based on benzoyl peroxide and at least one other active ingredient.
EP0738510A2 (en) Use of an HMG-CoA reductase as anti-ageing agent
EP0639068A1 (en) Acne treating composition
FR2555898A1 (en) ANTI-ACNEIC COMPOSITION BASED ON BENZOYL PEROXIDE AND AT LEAST ONE SOLAR FILTER
FR2909000A1 (en) COMPOSITIONS COMPRISING BENZOYL PEROXIDE, AT LEAST ONE NAPHTHOIC ACID DERIVATIVE AND AT LEAST ONE POLYURETHANE POLYMER COMPOUND OR DERIVATIVES THEREOF, AND USES THEREOF.
EP1781243A2 (en) Methods of managing the redness associated with a dermatological condition
CA2531186C (en) Use of an antioxidant in a dermatological and/or cosmetic composition
EP2019663A2 (en) Compositions comprising at least one naphthoic acid derivative and benzoyl peroxide, methods for preparing same, and uses thereof
CA2216574C (en) High electrolyte content oil-in-water emulsion and its use for dermatological/cosmetic purposes, specifically for treating irritated and/or sensitive skin.
EP0771557B1 (en) Use of ascorbic acid as the active agent for the treatment of seborrhea in a cosmetic and/or dermatalogical composition
FR2849597A1 (en) Cosmetic composition for treating greasy skin, contains a dicarboxylic fatty acid or derivative, reduces secretion of sebum and inhibits lipogenesis
CN1411360A (en) Method of treating skin conditions
FR2916975A1 (en) COMPOSITIONS COMPRISING AT LEAST ONE RETINOID COMPOUND, ANTI-IRRITANT COMPOUND AND BENZOYL PEROXIDE, AND USES THEREOF
FR2916966A1 (en) COMPOSITIONS COMPRISING AT LEAST ONE RETINOID COMPOUND, ANTI-IRRITANT COMPOUND AND BENZOYL PEROXIDE, AND USES THEREOF
EP0697206B1 (en) Cosmetic or pharmaceutical microemulsion and uses thereof
FR2718640A1 (en) Cosmetic and / or dermatological composition, in particular for depigmenting the skin, its uses.
FR2823671A1 (en) Dermatological compositions, useful for treating acne or atopic dermatitis, comprise synergistic combination of nicotinic acid or its amide and sphingoid base
CA2578121A1 (en) Use of metronidazole combined with azelaic acid for the treatment of rosacea
WO2002047652A1 (en) Composition containing 7-hydroxy dhea and/or 7-keto dhea and at least an antimicrobial agent
EP0940140A1 (en) Topical composition of alpha hydroxy acids and ceramides for the treatment of skin conditions
EP1916993B1 (en) Cosmetic composition containing a protease activator
FR2897534A1 (en) USE OF TESAGLITAZAR FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DERMATOLOGICAL DISEASES

Legal Events

Date Code Title Description
CL Concession to grant licences
CL Concession to grant licences
AU Other action affecting the ownership or exploitation of an industrial property right
PLFP Fee payment

Year of fee payment: 19

PLFP Fee payment

Year of fee payment: 20